Replicel Life Sciences Inc (REPCF) 0.0740 $REPCF
RepliCel Life Sciences Continues Restructuring With Share Structure Consolidation
Marketwire Canada - Fri Jul 22, 6:06PM CDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jul 22, 2016) - RepliCel Life Sciences Inc. ("RepliCel" or the "Company"
(OTCQB:REPCF)(TSX VENTURE:RP) (FRANKFURT
6P1), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that its Board of Directors has authorized a plan to proceed with a consolidation of its outstanding common shares (each, a "Share" on the basis of ten (10) pre-consolidation Shares for one (1) post-consolidation Share (the "Consolidation" .
RP.VN: 0.105 (+0.005)
RepliCel Life Sciences Conducts Formal Consultation Review With Japan's PMDA and Receives Unprecedented Review Fee Reduction
Marketwire Canada - Mon Apr 25, 7:00AM CDT
RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSX VENTURE:RP)(FRANKFURT 6P1), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced that it met this month with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) in Tokyo. The meeting was a formal consultation review of the company's pre-clinical, quality, and manufacturing data related to its non-bulbar dermal sheath (NBDS) platform technology. This review is a required step in the process to obtain PMDA consent to perform a clinical trial in Japan.
RP.VN: 0.105 (+0.005)
RepliCel Life Sciences Finishes Enrolment for its Tendon Repair and Skin Rejuvenation Clinical Trials
Marketwired - Wed Apr 20, 7:02AM CDT
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX VENTURE: RP) (FRANKFURT: P6P1), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that it has enrolled its final patients for both its RCT-01 and RCS-01 clinical trials. This ensures clinical data for both trials will be analyzed and released near year-end. Positive safety data will allow the company to move forward with phase 2 trials for both products in 2017. Data pertaining to the products' effects post-injection will inform and guide the company's product development and clinical trial strategy for both tendon repair and skin rejuvenation applications.
RP.VN: 0.105 (+0.005)
RepliCel Life Sciences Applies to Amend Warrant Exercise Price and Extend Warrant Expiry Dates
Marketwired - Fri Apr 08, 6:34PM CDT
RepliCel Life Sciences Inc. ("RepliCel" or the "Company" (OTCQB: REPCF) (TSX VENTURE: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that it has applied to the TSX Venture Exchange (the "TSXV" to extend the term of 2,043,555 share purchase warrants (the "Warrants" . The original term of 1,643,555 of the Warrants was two years and expired on April 10, 2015 and the original term of 400,000 of the Warrants was two years and expired on May 21, 2015. The Company previously received an extension from the TSXV for an additional year for the Warrants so that 1,643,555 Warrants will expire on April 10, 2016 and 400,000 Warrants will expire on May 21, 2016. The Company proposes to extend the expiry date for a further one year period to April 10, 2017 for 1,643,555 of the Warrants and to May 21, 2017 for 400,000 of the Warrants. In all other respects the terms of the Warrants will remain unchanged and in full force and effect.
RP.VN: 0.105 (+0.005)
RepliCel Life Sciences Announces Restructuring, Cost Reductions and Closing of Private Placement
Marketwire Canada - Wed Apr 06, 7:00AM CDT
RepliCel Life Sciences Inc. ("RepliCel" or the "Company" (OTCQB:REPCF) (TSX VENTURE:RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that its Board of Directors has authorized a plan to downsize all non-critical programs and staff in an effort to preserve capital to focus on the following three essential priorities pending a major financing or corporate transaction: (1) continued protection of intellectual property, (2) assembling of data from the RCT-01 and RCS-01 clinical trials expected near year-end 2016, and (3) the completion of a licensing/co-development transaction related to one of the four products the Company has in development (the "Critical Interim Priorities" .
RP.VN: 0.105 (+0.005)
Global Ageing Development Pipeline Review, H2 2015
M2 - Wed Jan 27, 4:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/3tlrh3/ageing_pipeline) has announced the addition of the "Ageing - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ageing, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ageing and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Ageing Overview - Therapeutics Development - Pipeline Products for Ageing - Overview - Pipeline Products for Ageing - Comparative Analysis - Ageing - Therapeutics under Development by Companies - Ageing - Therapeutics under Investigation by Universities/Institutes - Ageing - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Ageing - Products under Development by Companies - Ageing - Products under Investigation by Universities/Institutes - Ageing - Companies Involved in Therapeutics Development - Bioo Therapeutics - Mapreg S.A.S. - Neuralstem, Inc. - RepliCel Life Sciences, Inc. - RXi Pharmaceuticals Corporation - Theravasc, Inc. - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/3t...g_pipeline
CUR: 0.24 (unch)
VANC Pharmaceuticals Appointment of Mr. David Hall to Its Board of Directors
Marketwired - Thu Jan 21, 6:01AM CST
VANC Pharmaceuticals Inc. ("VANC" or the "Company" (TSX VENTURE: NPH)(OTCQB: NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC" markets, is pleased to announce the appointment of Mr. David M. Hall to VANC's Board of Directors.
NPH.VN: 0.230 (-0.010)
RepliCel Receives European Patent for its Innovative Dermal Injector Technology
Marketwired - Mon Jan 11, 8:41AM CST
RepliCel Life Sciences Inc. (OTCQB: REPCF)(TSX VENTURE: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced that it has been granted a patent (EP2623146) by the European Patent Office for its injection device technologies. The first device being developed under this patent, RCI-02, is designed for injecting hyaluronic acid as a dermal filler. The device is also being developed for the injection of RepliCel's RCH-01 hair restoration and RCS-01 skin rejuvenation products. Future iterations of the technology and device will be optimized for other injectables such as drugs, vaccines, fat grafts, etc.
RP.VN: 0.105 (+0.005)
RepliCel Announces Completion of First Injections in Clinical Trial of RCS-01 for Skin Aging and UV-Damaged Skin
Marketwired - Thu Dec 17, 7:02AM CST
RepliCel Life Sciences Inc. (OTCQB: REPCF)(TSX VENTURE: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced that the first injections of study products have been completed in the phase 1 clinical study (NCT02391935) evaluating RCS-01, an autologous cell-based skin rejuvenation product. RepliCel is developing RCS-01 as a longer-lasting, more natural alternative to existing dermal fillers on the market which often have only short-term results.
RP.VN: 0.105 (+0.005)
RepliCel Life Sciences Announces Leadership Transition
Marketwired - Wed Dec 16, 8:04AM CST
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX VENTURE: RP) ("RepliCel" or the "Company" today announced that its Board of Directors (the "Board" has appointed Lee Buckler, formerly Vice President of Business and Corporate Development, the Company's new Chief Executive Officer and President, effective January 1, 2016. Mr. Buckler succeeds David Hall, who will retire as Chief Executive Officer at the end of the year after five years leading the Company.
RP.VN: 0.105 (+0.005)
RepliCel Executives to Present at 9th World Congress for Hair Research in Miami
PR Newswire - Thu Nov 12, 11:26AM CST
Conference brings together hair biologists, dermatologists, cosmetic scientists and leading biotech companies to discuss the advancement of knowledge in hair growth and research
RP.VN: 0.105 (+0.005)
Alopecia Pipeline Review, H2 2015
M2 - Fri Nov 06, 9:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/tzzxx2/alopecia) has announced the addition of the "Alopecia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Alopecia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alopecia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan Plc - AndroScience Corporation - Berg, LLC - Bristol-Myers Squibb Company - Dong-A Socio Group - Follicum AB - Histogen, Inc. - Hyundai Pharmaceutical Co., Ltd. - Kuhnil Pharmaceutical Co., Ltd. - Kythera Biopharmaceuticals, Inc. - Lee's Pharmaceutical Holdings Limited - Panacea Biotec Limited - Polichem S.A. - R-Tech Ueno, Ltd. - RepliCel Life Sciences, Inc. - RestorGenex Corporation - RXi Pharmaceuticals Corporation - SWITCH Biotech LLC - Taisho Pharmaceutical Co., Ltd. - Tigo GmbH - Valeant Pharmaceuticals International, Inc. - Vida Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/tzzxx2/alopecia
AGN: 252.95 (-2.61), BMY: 74.81 (+0.15), VRX.TO: 29.08 (-1.37)
RepliCel Selected as One of This Year's Top 20 Public Canadian Technology Companies
PR Newswire - Wed Nov 04, 7:00AM CST
Canadian Innovation Exchange (CIX) Public Investor Day November 18 at Toronto's MaRS Discovery District to showcase 'Canada's hottest and most innovative public technology companies'
RP.VN: 0.105 (+0.005)
RepliCel Life Sciences Continues Restructuring With Share Structure Consolidation
Marketwire Canada - Fri Jul 22, 6:06PM CDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jul 22, 2016) - RepliCel Life Sciences Inc. ("RepliCel" or the "Company"
(OTCQB:REPCF)(TSX VENTURE:RP) (FRANKFURT 6P1), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that its Board of Directors has authorized a plan to proceed with a consolidation of its outstanding common shares (each, a "Share" on the basis of ten (10) pre-consolidation Shares for one (1) post-consolidation Share (the "Consolidation" . RP.VN: 0.105 (+0.005)
RepliCel Life Sciences Conducts Formal Consultation Review With Japan's PMDA and Receives Unprecedented Review Fee Reduction
Marketwire Canada - Mon Apr 25, 7:00AM CDT
RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSX VENTURE:RP)(FRANKFURT
6P1), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced that it met this month with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) in Tokyo. The meeting was a formal consultation review of the company's pre-clinical, quality, and manufacturing data related to its non-bulbar dermal sheath (NBDS) platform technology. This review is a required step in the process to obtain PMDA consent to perform a clinical trial in Japan. RP.VN: 0.105 (+0.005)
RepliCel Life Sciences Finishes Enrolment for its Tendon Repair and Skin Rejuvenation Clinical Trials
Marketwired - Wed Apr 20, 7:02AM CDT
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX VENTURE: RP) (FRANKFURT: P6P1), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that it has enrolled its final patients for both its RCT-01 and RCS-01 clinical trials. This ensures clinical data for both trials will be analyzed and released near year-end. Positive safety data will allow the company to move forward with phase 2 trials for both products in 2017. Data pertaining to the products' effects post-injection will inform and guide the company's product development and clinical trial strategy for both tendon repair and skin rejuvenation applications.
RP.VN: 0.105 (+0.005)
RepliCel Life Sciences Applies to Amend Warrant Exercise Price and Extend Warrant Expiry Dates
Marketwired - Fri Apr 08, 6:34PM CDT
RepliCel Life Sciences Inc. ("RepliCel" or the "Company"
(OTCQB: REPCF) (TSX VENTURE: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that it has applied to the TSX Venture Exchange (the "TSXV" to extend the term of 2,043,555 share purchase warrants (the "Warrants" . The original term of 1,643,555 of the Warrants was two years and expired on April 10, 2015 and the original term of 400,000 of the Warrants was two years and expired on May 21, 2015. The Company previously received an extension from the TSXV for an additional year for the Warrants so that 1,643,555 Warrants will expire on April 10, 2016 and 400,000 Warrants will expire on May 21, 2016. The Company proposes to extend the expiry date for a further one year period to April 10, 2017 for 1,643,555 of the Warrants and to May 21, 2017 for 400,000 of the Warrants. In all other respects the terms of the Warrants will remain unchanged and in full force and effect. RP.VN: 0.105 (+0.005)
RepliCel Life Sciences Announces Restructuring, Cost Reductions and Closing of Private Placement
Marketwire Canada - Wed Apr 06, 7:00AM CDT
RepliCel Life Sciences Inc. ("RepliCel" or the "Company"
(OTCQB:REPCF) (TSX VENTURE:RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that its Board of Directors has authorized a plan to downsize all non-critical programs and staff in an effort to preserve capital to focus on the following three essential priorities pending a major financing or corporate transaction: (1) continued protection of intellectual property, (2) assembling of data from the RCT-01 and RCS-01 clinical trials expected near year-end 2016, and (3) the completion of a licensing/co-development transaction related to one of the four products the Company has in development (the "Critical Interim Priorities" . RP.VN: 0.105 (+0.005)
Global Ageing Development Pipeline Review, H2 2015
M2 - Wed Jan 27, 4:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/3tlrh3/ageing_pipeline) has announced the addition of the "Ageing - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ageing, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ageing and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Ageing Overview - Therapeutics Development - Pipeline Products for Ageing - Overview - Pipeline Products for Ageing - Comparative Analysis - Ageing - Therapeutics under Development by Companies - Ageing - Therapeutics under Investigation by Universities/Institutes - Ageing - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Ageing - Products under Development by Companies - Ageing - Products under Investigation by Universities/Institutes - Ageing - Companies Involved in Therapeutics Development - Bioo Therapeutics - Mapreg S.A.S. - Neuralstem, Inc. - RepliCel Life Sciences, Inc. - RXi Pharmaceuticals Corporation - Theravasc, Inc. - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/3t...g_pipeline
CUR: 0.24 (unch)
VANC Pharmaceuticals Appointment of Mr. David Hall to Its Board of Directors
Marketwired - Thu Jan 21, 6:01AM CST
VANC Pharmaceuticals Inc. ("VANC" or the "Company"
(TSX VENTURE: NPH)(OTCQB: NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC" markets, is pleased to announce the appointment of Mr. David M. Hall to VANC's Board of Directors. NPH.VN: 0.230 (-0.010)
RepliCel Receives European Patent for its Innovative Dermal Injector Technology
Marketwired - Mon Jan 11, 8:41AM CST
RepliCel Life Sciences Inc. (OTCQB: REPCF)(TSX VENTURE: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced that it has been granted a patent (EP2623146) by the European Patent Office for its injection device technologies. The first device being developed under this patent, RCI-02, is designed for injecting hyaluronic acid as a dermal filler. The device is also being developed for the injection of RepliCel's RCH-01 hair restoration and RCS-01 skin rejuvenation products. Future iterations of the technology and device will be optimized for other injectables such as drugs, vaccines, fat grafts, etc.
RP.VN: 0.105 (+0.005)
RepliCel Announces Completion of First Injections in Clinical Trial of RCS-01 for Skin Aging and UV-Damaged Skin
Marketwired - Thu Dec 17, 7:02AM CST
RepliCel Life Sciences Inc. (OTCQB: REPCF)(TSX VENTURE: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced that the first injections of study products have been completed in the phase 1 clinical study (NCT02391935) evaluating RCS-01, an autologous cell-based skin rejuvenation product. RepliCel is developing RCS-01 as a longer-lasting, more natural alternative to existing dermal fillers on the market which often have only short-term results.
RP.VN: 0.105 (+0.005)
RepliCel Life Sciences Announces Leadership Transition
Marketwired - Wed Dec 16, 8:04AM CST
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX VENTURE: RP) ("RepliCel" or the "Company"
today announced that its Board of Directors (the "Board" has appointed Lee Buckler, formerly Vice President of Business and Corporate Development, the Company's new Chief Executive Officer and President, effective January 1, 2016. Mr. Buckler succeeds David Hall, who will retire as Chief Executive Officer at the end of the year after five years leading the Company. RP.VN: 0.105 (+0.005)
RepliCel Executives to Present at 9th World Congress for Hair Research in Miami
PR Newswire - Thu Nov 12, 11:26AM CST
Conference brings together hair biologists, dermatologists, cosmetic scientists and leading biotech companies to discuss the advancement of knowledge in hair growth and research
RP.VN: 0.105 (+0.005)
Alopecia Pipeline Review, H2 2015
M2 - Fri Nov 06, 9:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/tzzxx2/alopecia) has announced the addition of the "Alopecia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Alopecia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alopecia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan Plc - AndroScience Corporation - Berg, LLC - Bristol-Myers Squibb Company - Dong-A Socio Group - Follicum AB - Histogen, Inc. - Hyundai Pharmaceutical Co., Ltd. - Kuhnil Pharmaceutical Co., Ltd. - Kythera Biopharmaceuticals, Inc. - Lee's Pharmaceutical Holdings Limited - Panacea Biotec Limited - Polichem S.A. - R-Tech Ueno, Ltd. - RepliCel Life Sciences, Inc. - RestorGenex Corporation - RXi Pharmaceuticals Corporation - SWITCH Biotech LLC - Taisho Pharmaceutical Co., Ltd. - Tigo GmbH - Valeant Pharmaceuticals International, Inc. - Vida Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/tzzxx2/alopecia
AGN: 252.95 (-2.61), BMY: 74.81 (+0.15), VRX.TO: 29.08 (-1.37)
RepliCel Selected as One of This Year's Top 20 Public Canadian Technology Companies
PR Newswire - Wed Nov 04, 7:00AM CST
Canadian Innovation Exchange (CIX) Public Investor Day November 18 at Toronto's MaRS Discovery District to showcase 'Canada's hottest and most innovative public technology companies'
RP.VN: 0.105 (+0.005)
